Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > New Press Release - Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 27, 2024 9:12pm

199 Views

Post# 36110067

RE:New Press Release - Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

- Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer

- The FDA supports progression-free survival as the primary endpoint of the study, with overall survival as a key secondary endpoint

- Metastatic breast cancer overall survival (OS) results to be released this H2'24

<< Previous

Bullboard Posts

Next >>

DRI Healthcare stock drops 28% after executive changes